NCT03965546View on ClinicalTrials.gov

ET 140202 -T Cell Combined With TAE or Sorafenib in the Treatment of Liver Cancer

EARLY_PHASE1UnknownINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

May 30, 2019

Primary Completion Date

June 30, 2021

Study Completion Date

June 30, 2022

Conditions
Hepatocellular CarcinomaLiver CancerLiver NeoplasmsMetastatic Liver Cancer
Interventions
COMBINATION_PRODUCT

Sorafenib combined with ET140202-T cell

"1. Sorafenib starting dose of 400mg b.i.d. a.c.~2. Autologous T cells transduced with lentivirus encoding an anti-AFP (ET140202) expression construct by intravenous (IV) infusion"

COMBINATION_PRODUCT

TAE combined with ET140202-T cell

"1. Transarterial embolization(TAE) treatment~2. Autologous T cells transduced with lentivirus encoding an anti-AFP (ET140202) expression construct -intravenous (i.v.)"

BIOLOGICAL

ET140202-T cell

Autologous T cells transduced with lentivirus encoding an anti-AFP (ET140202) - expression construct -intravenous (i.v.)

Trial Locations (1)

710061

RECRUITING

The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an

Sponsors

Collaborators (1)

Eureka Therapeutics Inc.
All Listed Sponsors
collaborator

Eureka Therapeutics Inc.

INDUSTRY

lead

First Affiliated Hospital Xi'an Jiaotong University

OTHER